Trial Profile
A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome (MDS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 07 Feb 2017 Status changed from active, no longer recruiting to completed.
- 07 Feb 2017 Status changed from active, no longer recruiting to completed.
- 19 Nov 2016 Planned End Date changed from 1 Dec 2020 to 1 Mar 2017.